2023-03-08
In December 2022, Zhimeng Biopharma entered into a Global Exclusive license agreement with GSK for CB06, a TLR8 agonist. Subject to successful completion of phase I, the agreement will allow GSK to develop, manufacture and commercialise CB06 for the treatment of HBV. If successful, CB06 could be used in combination, or as a sequential treatment with bepirovirsen, to potentially deliver a functional cure in more HBV patients.
Scan QR code
Focus on the official account of Great Filter Venture
Address: 3306 Hanjing financial center, 9968 Shennan Avenue, Nanshan District, Shenzhen
Email: info@szdawu.com
Tel: 0755-33390023